Neuroactiva, Inc

NeuroActiva, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of new drugs to treat Alzheimer’s disease. NeuroActiva, Inc. is a wholly owned subsidiary of Biomed Industries, Traneurocin (NA-831): NeuroActiva has developed a new platform of products are designed to protect and repair damage caused by disease, trauma or old age, as well as to regenerate new neurons to activate the neurotransmission to restore the cognitive and mental capacity of Alzheimer patients. Our first drug candidate in clinical development is NA-831 (Traneurocin) which has excellent safety profile with no adverse effects observed. The drug is administered orally in a dosage form for the treatment of Alzheimer's disease. We have completed the Phase 2A for NA-831 with a proof of safety and efficacy. We plan to launch a Phase 2B/ 3 for NA-831 in 2022. Vineurocin (NA-704): Our second drug candidate, Vineurocin (NA-704) that can regulate cell growth and development, especially in nerve cells, as well as cellular DNA synthesis. NA-704 exhibits neuroprotection and neurogenesis, which has been demonstrated as a strong candidate for treatment of Alzheimer’s disease and other neurological disorders. NA-704 is administered intravenously once a week, per prescription of a qualified physician. MICROS Controlled Release Infusion System: Besides biopharmaceutical, NeuroActiva has developed an advanced intravenous drug delivery, known as the MICROS Infusion System, which can be pre-filled with NA-704 to control release an accurate amount of the dosage to patient in hospital as well as in homecare setting. The MICROS infusion system has been approved for marketing in the USA.